hotspot -WSS

hotspot

author：comprehensive 2025-10-02 00:42:48 - browse：441

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： The painfully weak evidence on taking collagen to treat arthritis

focus

WSS

5 important ways Henrietta Lacks changed medical science

Former Georgia lieutenant governor says he received grand jury subpoena

No plane should take off without an EpiPen onboard

Sage hopes for a blockbuster in antidepressant now before FDA

The high personal cost of affirmative action for Black doctors

CDC launches VaccineFinder tool to locate Covid

entertainment

hotspot

explore

Trump demands the U.S. pay no more for drugs than other countries … again

What the airline industry can learn from medicine

Malaria cases in Florida and Texas: Here’s what you need to know

Lawsuit alleges UnitedHealth Group unit illegally denied claims

United colonoscopy coverage change 'may cost lives,' doctors say

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Cancer drug shortages should be causing more outrage

5 important ways Henrietta Lacks changed medical science

The cancer drug shortage isn’t new — and neither are the solutions

In venture capital firm's success, lessons for turning crisis into profit

leisure time

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Sage hopes for a blockbuster in antidepressant now before FDA

Germany receives 178 compensation applications from gay servicepeople over discrimination

hotspot

explore

focus

knowledge